Literature DB >> 34310198

Second-Generation Bruton's Tyrosine Kinase Inhibitors: Simply the Best Treatments for Chronic Lymphocytic Leukemia?

Deborah M Stephens1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34310198      PMCID： PMC8547933          DOI： 10.1200/JCO.21.01414

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  25 in total

1.  Cardiovascular Toxicities Associated With Ibrutinib.

Authors:  Joe-Elie Salem; Ali Manouchehri; Marie Bretagne; Bénédicte Lebrun-Vignes; John D Groarke; Douglas B Johnson; Tao Yang; Nishitha M Reddy; Christian Funck-Brentano; Jennifer R Brown; Dan M Roden; Javid J Moslehi
Journal:  J Am Coll Cardiol       Date:  2019-10-01       Impact factor: 24.094

2.  Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo.

Authors:  Junling Liu; Malinda E Fitzgerald; Michael C Berndt; Carl W Jackson; T Kent Gartner
Journal:  Blood       Date:  2006-06-20       Impact factor: 22.113

3.  ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.

Authors:  Paolo Ghia; Andrzej Pluta; Malgorzata Wach; Daniel Lysak; Tomas Kozak; Martin Simkovic; Polina Kaplan; Iryna Kraychok; Arpad Illes; Javier de la Serna; Sean Dolan; Phillip Campbell; Gerardo Musuraca; Abraham Jacob; Eric Avery; Jae Hoon Lee; Wei Liang; Priti Patel; Cheng Quah; Wojciech Jurczak
Journal:  J Clin Oncol       Date:  2020-05-27       Impact factor: 44.544

4.  Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.

Authors:  Jeff P Sharman; Miklos Egyed; Wojciech Jurczak; Alan Skarbnik; John M Pagel; Ian W Flinn; Manali Kamdar; Talha Munir; Renata Walewska; Gillian Corbett; Laura Maria Fogliatto; Yair Herishanu; Versha Banerji; Steven Coutre; George Follows; Patricia Walker; Karin Karlsson; Paolo Ghia; Ann Janssens; Florence Cymbalista; Jennifer A Woyach; Gilles Salles; William G Wierda; Raquel Izumi; Veerendra Munugalavadla; Priti Patel; Min Hui Wang; Sofia Wong; John C Byrd
Journal:  Lancet       Date:  2020-04-18       Impact factor: 79.321

5.  A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.

Authors:  Constantine S Tam; Stephen Opat; Shirley D'Sa; Wojciech Jurczak; Hui-Peng Lee; Gavin Cull; Roger G Owen; Paula Marlton; Björn E Wahlin; Ramón Garcia Sanz; Helen McCarthy; Stephen Mulligan; Alessandra Tedeschi; Jorge J Castillo; Jaroslaw Czyz; Carlos Fernández de Larrea; David Belada; Edward Libby; Jeffrey V Matous; Marina Motta; Tanya Siddiqi; Monica Tani; Marek Trneny; Monique C Minnema; Christian Buske; Veronique Leblond; Judith Trotman; Wai Y Chan; Jingjing Schneider; Sunhee Ro; Aileen Cohen; Jane Huang; Meletios Dimopoulos
Journal:  Blood       Date:  2020-10-29       Impact factor: 22.113

6.  Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth.

Authors:  Jun Chen; Taisei Kinoshita; Juthamas Sukbuntherng; Betty Y Chang; Laurence Elias
Journal:  Mol Cancer Ther       Date:  2016-09-27       Impact factor: 6.261

7.  Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation.

Authors:  Lynette Pretorius; Xiao-Jun Du; Elizabeth A Woodcock; Helen Kiriazis; Ruby C Y Lin; Silvana Marasco; Robert L Medcalf; Ziqiu Ming; Geoffrey A Head; Joon Win Tan; Nelly Cemerlang; Junichi Sadoshima; Tetsuo Shioi; Seigo Izumo; Elena V Lukoshkova; Anthony M Dart; Garry L Jennings; Julie R McMullen
Journal:  Am J Pathol       Date:  2009-08-13       Impact factor: 4.307

8.  Hypertension and incident cardiovascular events following ibrutinib initiation.

Authors:  Tyler Dickerson; Tracy Wiczer; Allyson Waller; Jennifer Philippon; Kyle Porter; Devin Haddad; Avirup Guha; Kerry A Rogers; Seema Bhat; John C Byrd; Jennifer A Woyach; Farrukh Awan; Daniel Addison
Journal:  Blood       Date:  2019-11-28       Impact factor: 22.113

9.  Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.

Authors:  John C Byrd; Peter Hillmen; Susan O'Brien; Jacqueline C Barrientos; Nishitha M Reddy; Steven Coutre; Constantine S Tam; Stephen P Mulligan; Ulrich Jaeger; Paul M Barr; Richard R Furman; Thomas J Kipps; Patrick Thornton; Carol Moreno; Marco Montillo; John M Pagel; Jan A Burger; Jennifer A Woyach; Sandra Dai; Remus Vezan; Danelle F James; Jennifer R Brown
Journal:  Blood       Date:  2019-03-06       Impact factor: 25.476

10.  Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.

Authors:  Arnon P Kater; Jenny Qun Wu; Thomas Kipps; Barbara Eichhorst; Peter Hillmen; James D'Rozario; Sarit Assouline; Carolyn Owen; Tadeusz Robak; Javier de la Serna; Ulrich Jaeger; Guillaume Cartron; Marco Montillo; Julie Dubois; Eric Eldering; Clemens Mellink; Anne-Marie Van Der Kevie-Kersemaekers; Su Young Kim; Brenda Chyla; Elizabeth Punnoose; Christopher R Bolen; Zoe June Assaf; Yanwen Jiang; Jue Wang; Marcus Lefebure; Michelle Boyer; Kathryn Humphrey; John F Seymour
Journal:  J Clin Oncol       Date:  2020-09-28       Impact factor: 44.544
View more
  1 in total

Review 1.  The Role of Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions.

Authors:  Tadeusz Robak; Magda Witkowska; Piotr Smolewski
Journal:  Cancers (Basel)       Date:  2022-02-02       Impact factor: 6.639
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.